Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

A pediatric oncologist looks for progress in Alzheimer’s disease

Ron Louie, MD
Conditions
May 8, 2018
Share
Tweet
Share

A baby acutely ill with leukemia seems like the polar opposite of a woman with Alzheimer’s disease (AD), with her slow, insidious deterioration. Yet each disease can be progressive and fatal. I’ve cared for both, in different ways.  Can a childhood cancer doctor like me have insights about that other end of medicine, older adults with dementia?

As a husband and caregiver, confronting my wife’s Alzheimer’s disease, I am appalled by the lack of effective therapy for her. As a clinical investigator myself, I’m appalled by what I see as a lack of direction in clinical dementia research, a lack of structure, and a lack of ambitious leadership.

Every Minute Counts, the PBS TV documentary that aired recently, showed the heart-rending personal devastation of Alzheimer’s Disease (AD) and dementia, and the enormous cost of care for those affected.  It ended with a plea for more funding and research. But after decades of research and billions already spent, why aren’t we further?

Alzheimer’s is now the 6th leading cause of death in the U.S.; it was only 13th two decades ago. Many AD experts acknowledge the lack of progress. Recently, two researchers even wrote that seeking an AD cure is a notion “many believe unrealistic,” and that advocating for curative therapy “verges on the promotion of false hope.”

Since my wife was diagnosed, just one new drug, really a combination of two older drugs, has been approved for Alzheimer’s.  As a cancer doctor, I’ve watched more than 70 cancer treatments get approved during those same five years.

Even the Alzheimer’s Association plainly states “there is no cure for Alzheimer’s.”  Not so plainly stated is that we don’t know what causes it, how it happens, or how to prevent it.

Of course, we don’t really know what causes childhood leukemia either, how it happens, or how to prevent it, even with our current sophisticated molecular descriptions and theories.  But the survival rate for the most common childhood leukemia has gone from less than 10% in the 1960’s to over 90% now, with incremental progress every five years.  Most kids are cured with combination chemotherapy that was developed decades ago, before molecular testing.

Most AD funding goes for molecular or non-therapeutic research, at the expense of clinical work. Sickle cell anemia was called the first “molecular disease” over sixty years ago; we still don’t have a cure, even though just this year we might have a gene therapy for it. In AD, the molecular genetics seems more complicated. AD patients have waited years for ANY therapy, much less one from “precision medicine.” Is this the right strategy?

It’s not all bad news. Recently, three commercial drug trials announced results, and they showed glimmers of hope.  Two were reported as failures by the media, but company press releases (TauRx,Lilly) reported modest positive effects. The third drug, from Biogen, seemed better at slowing the decline in some patients, but evidently did not stop the disease.

AIDS therapy, like cancer, is an area of medicine that seemed hopeless at first.  The leadership of Dr. William Paul, an “AIDS Czar,” is credited with accelerating clinical progress in that condition.  Still incurable, nevertheless AIDS patients’ lives are now extended from months to years.

Nothing has really changed for Alzheimer patients over the past five years. Brilliant scientists are working, but in the usual atmosphere of creative academic chaos. There are a few AD clinical trial groups, much like cancer trials groups, but the comparison of their activity is stark. In the state of Washington, there are over 600 cancer studies recruiting patients; in AD there are about a dozen such studies.

Much foundational AD work still needs to be done at the bedside, in overall strategy, trial coordination, informed consents, vigorous subject recruitment, and consensus development, so appointing an accountable, identifiable, directive clinical research leader seems like an important way to accelerate progress (although “czar” or “emperor” may not be the right titles these days).

Ron Louie is a pediatric oncologist.  This article originally appeared in the Baltimore Sun.

ADVERTISEMENT

Image credit: Shutterstock.com

Prev

Undoing what we’ve done: Why deprescribing is so difficult

May 8, 2018 Kevin 3
…
Next

Addressing the health care system flaws that feed the opioid crisis

May 8, 2018 Kevin 21
…

Tagged as: Neurology

Post navigation

< Previous Post
Undoing what we’ve done: Why deprescribing is so difficult
Next Post >
Addressing the health care system flaws that feed the opioid crisis

ADVERTISEMENT

More by Ron Louie, MD

  • Will Alzheimer’s disease researchers miss seeing the forest from the trees?

    Ron Louie, MD
  • Do substituted decisions break the Golden Rule?

    Ron Louie, MD
  • Interpreting 2 recent studies involving Alzheimer disease

    Ron Louie, MD

Related Posts

  • Should only infectious disease specialists be allowed to prescribe antibiotics?

    Craig Bowron, MD
  • The culture of perfection in medicine is a disease

    Andy Cruz, MD
  • Chronic disease is making medical education worse

    Jason J. Han, MD
  • Observing the effects of COVID-19 on the pediatric population

    Amy Cox and Rachel Kalthoff
  • 10 tips for delivering difficult pediatric diagnoses

    Laura Spiegel
  • Are pediatric hospitals ready to embrace value-based payment models?

    Johanna Vidal Phelan, MD, MBA

More in Conditions

  • Why PSA levels alone shouldn’t define your prostate cancer risk

    Martina Ambardjieva, MD, PhD
  • Reframing chronic pain and dignity: What a pain clinic teaches us about MAiD and chronic suffering

    Olumuyiwa Bamgbade, MD
  • America’s ER crisis: Why the system is collapsing from within

    Kristen Cline, BSN, RN
  • Why timing, not surgery, determines patient survival

    Michael Karch, MD
  • Why psychotherapy works and why psychotherapy fails

    Peggy A. Rothbaum, PhD
  • How oral health silently affects your heart, brain, and body

    Charles Reinertsen, DMD
  • Most Popular

  • Past Week

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why timing, not surgery, determines patient survival

      Michael Karch, MD | Conditions
    • Why health care leaders fail at execution—and how to fix it

      Dave Cummings, RN | Policy
    • How digital tools are reshaping the doctor-patient relationship

      Vineet Vishwanath | Tech
  • Past 6 Months

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
  • Recent Posts

    • Why point-of-care ultrasound belongs in every emergency department triage [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why PSA levels alone shouldn’t define your prostate cancer risk

      Martina Ambardjieva, MD, PhD | Conditions
    • How to handle chronically late patients in your medical practice

      Neil Baum, MD | Physician
    • Reframing chronic pain and dignity: What a pain clinic teaches us about MAiD and chronic suffering

      Olumuyiwa Bamgbade, MD | Conditions
    • How early meetings and after-hours events penalize physician-mothers

      Samira Jeimy, MD, PhD and Menaka Pai, MD | Physician
    • Why medicine must evolve to support modern physicians

      Ryan Nadelson, MD | Physician

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 1 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why timing, not surgery, determines patient survival

      Michael Karch, MD | Conditions
    • Why health care leaders fail at execution—and how to fix it

      Dave Cummings, RN | Policy
    • How digital tools are reshaping the doctor-patient relationship

      Vineet Vishwanath | Tech
  • Past 6 Months

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
  • Recent Posts

    • Why point-of-care ultrasound belongs in every emergency department triage [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why PSA levels alone shouldn’t define your prostate cancer risk

      Martina Ambardjieva, MD, PhD | Conditions
    • How to handle chronically late patients in your medical practice

      Neil Baum, MD | Physician
    • Reframing chronic pain and dignity: What a pain clinic teaches us about MAiD and chronic suffering

      Olumuyiwa Bamgbade, MD | Conditions
    • How early meetings and after-hours events penalize physician-mothers

      Samira Jeimy, MD, PhD and Menaka Pai, MD | Physician
    • Why medicine must evolve to support modern physicians

      Ryan Nadelson, MD | Physician

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

A pediatric oncologist looks for progress in Alzheimer’s disease
1 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...